GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Cyclically Adjusted PB Ratio

Regeneron Pharmaceuticals (WBO:REGN) Cyclically Adjusted PB Ratio : 8.56 (As of May. 16, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Regeneron Pharmaceuticals's current share price is €910.20. Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €106.37. Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 8.56.

The historical rank and industry rank for Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:REGN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.04   Med: 15.22   Max: 62.14
Current: 8.52

During the past years, Regeneron Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 62.14. The lowest was 7.04. And the median was 15.22.

WBO:REGN's Cyclically Adjusted PB Ratio is ranked worse than
87.46% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs WBO:REGN: 8.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €225.363. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €106.37 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.38 10.52 9.95 8.39 8.03

Regeneron Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.89 7.30 7.88 8.03 8.39

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=910.20/106.37
=8.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=225.363/131.7762*131.7762
=225.363

Current CPI (Mar. 2024) = 131.7762.

Regeneron Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 17.170 100.560 22.500
201409 19.381 100.428 25.431
201412 20.192 99.070 26.858
201503 26.598 99.621 35.183
201506 28.701 100.684 37.564
201509 28.231 100.392 37.057
201512 32.061 99.792 42.337
201603 32.202 100.470 42.236
201606 34.461 101.688 44.658
201609 37.944 101.861 49.088
201612 39.788 101.863 51.472
201703 42.815 102.862 54.850
201706 45.868 103.349 58.484
201709 47.273 104.136 59.821
201712 48.239 104.011 61.116
201803 49.386 105.290 61.810
201806 56.982 106.317 70.627
201809 62.315 106.507 77.100
201812 70.617 105.998 87.791
201903 76.276 107.251 93.719
201906 78.646 108.070 95.898
201909 86.929 108.329 105.744
201912 90.506 108.420 110.003
202003 97.872 108.902 118.430
202006 75.856 108.767 91.903
202009 80.625 109.815 96.749
202012 84.738 109.897 101.609
202103 94.339 111.754 111.241
202106 117.650 114.631 135.246
202109 135.200 115.734 153.940
202112 152.845 117.630 171.227
202203 165.127 121.301 179.387
202206 178.727 125.017 188.390
202209 199.018 125.227 209.427
202212 195.208 125.222 205.426
202303 200.041 127.348 206.997
202306 203.568 128.729 208.387
202309 214.445 129.860 217.610
202312 217.673 129.419 221.637
202403 225.363 131.776 225.363

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (WBO:REGN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (WBO:REGN) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).